INBISTRA Partners with AseBio to Strengthen Spain's Biotech Ecosystem

What does your company's work bring to the table and what is its strength?

INBISTRA is a management consulting firm that bridges the critical gap between groundbreaking research and viable therapeutic development. Our team brings decades of experience from leading research institutions across Europe and the USA, having led R&D departments in big and mid-sized pharma companies as well as biotechs. With a track record of high-profile publications, 5 INDs, 2 FDA fast-track designations, and one commercial first-in-class therapeutic, our strength lies in real-world drug discovery expertise spanning multiple therapeutic areas and modalities, from small molecules to advanced therapeutics—including antibodies, cell therapies, and gene-editing platforms.

We focus on early-stage decision making where traditional analytical and valuation models often fall short. While risk-adjusted NPV (rNPV) models provide valuable frameworks for mature programs, early-stage assets require more nuanced approaches that account for platform potential, regulatory pathway uncertainties, and competitive landscape evolution. We develop systematic Go/No-Go frameworks and customized AI/ML models that integrate these multidimensional risk factors, enabling founders and investors to make informed decisions when data is limited but strategic direction is critical. Our approach transforms how preclinical programs assess their potential for advancement through evidence-based strategic analysis.

What is AseBio for you?

AseBio is a key player in Spain's biotech ecosystem. It serves as an integrator, connecting foundational academic research with the strategic and capital resources required for therapeutic translation. For INBISTRA, it is a platform to network and exchange validated frameworks with other innovators and contribute to the overall efficiency of the national drug discovery pipeline.

When did you first hear about AseBio?

I first heard about AseBio when I returned to Spain in September 2020 to take on the role of Executive Director of Drug Discovery for a pharma company. After spending over fifteen years abroad—mainly in the U.S.—my network was largely international. Reconnecting with the national biotech ecosystem became a priority, and I quickly recognized AseBio's pivotal role. I particularly appreciate its focus on the academic-industry interface, which is central to our work at INBISTRA in advancing new therapeutic discoveries.

What do you expect from being part of an association like AseBio?

We expect AseBio to serve as a strategic amplifier—connecting INBISTRA with the ecosystem of innovators, investors, and leaders who share our commitment to evidence- and data-driven therapeutic development. We aim to contribute proven frameworks for optimizing preclinical strategy and de-risking asset development. In return, we seek to learn from members who have navigated complex regulatory and market entry challenges. The objective is to help build a community that integrates rigorous scientific validation with disciplined strategic thinking to boost preclinical asset value while minimizing development risks.

What is the biggest challenge facing the biotech sector or your company?

The sector's primary challenge is the translation gap: promising science often fails due to a lack of strategic rigor during early development. Many discoveries don't fall short because the science is weak, but because critical decisions weren't guided by a structured strategic framework.

At INBISTRA, we address this by applying a hybrid scientific and business strategy to preclinical programs. We embed competitive analysis and robust risk assessment into stage-gate decisions, transforming how programs assess viability and create value. It means getting the science right—like an academic researcher—but also knowing how to turn that science into a successful therapy, like an experienced industry leader.